Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • BioAlliance, Innocutis sales and marketing update

    BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Innocutis Holdings LLC, Charleston, S.C. Business: Infectious BioAlliance granted Innocutis exclusive commercialization rights in North America for Sitavig acyclovir…

    Published on 3/24/2014
  • Cardiome, Logista Pharma sales and marketing update

    Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Logista Pharma S.A., Madrid, Spain Business: Cardiovascular Cardiome granted Logista rights to commercialize IV Brinavess vernakalant in Spain. Cardiome said…

    Published on 3/24/2014
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Starting next half, Gilead will provide HCV drug Sovaldi sofosbuvir in Egypt at $300 for a four-week supply - or $900 for a 12-week course of …

    Published on 3/24/2014
  • Good Start Genetics, PerkinElmer sales and marketing update

    Good Start Genetics Inc., Cambridge, Mass. PerkinElmer Inc. (NYSE:PKI), Waltham, Mass. Business: Diagnostic Good Start granted PerkinElmer exclusive rights to market the GoodStart Select carrier screening tests to …

    Published on 3/24/2014
  • Lundbeck, Otsuka Pharmaceutical sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Neurology H. Lundbeck and Otsuka launched once-monthly, intramuscular Abilify Maintena aripiprazole in Europe for …

    Published on 3/24/2014
  • Meda, Mission Pharmacal sales and marketing update

    Meda AB (SSE:MEDAA), Solna, Sweden Mission Pharmacal Co., San Antonio, Texas Business: Genitourinary Mission Pharmacal received rights to promote Meda's Elestrin estradiol gel in the U.S. The bioidentical estradiol …

    Published on 3/24/2014
  • NeoGenomics sales and marketing update

    NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla. Business: Pharmacogenetics NeoGenomics launched two next-generation sequencing cancer profiling tests. The myelodysplastic syndrome (MDS) test covers 16 genes and can be …

    Published on 3/24/2014
  • Novartis sales and marketing update

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Ophthalmic Novartis launched the Lucentis ranibizumab pre-filled syringe in Germany, with other markets to follow this year. The syringe, which is designed …

    Published on 3/24/2014
  • Qiagen sales and marketing update

    Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN), Venlo, the Netherlands Business: Diagnostic Qiagen launched QuantiFeron-TB Gold In-Tube blood test in China to diagnose Mycobacterium tuberculosis infection. The test was approved …

    Published on 3/24/2014
  • Quinnova sales and marketing update

    Quinnova Pharmaceuticals LLC, Jamison, Pa. Business: Dermatology Quinnova launched Ecoza econazole nitrate topical foam in the U.S. to treat interdigital tinea pedis in patients ages 12 years and older. Ecoza is a …

    Published on 3/24/2014
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche launched its cobas Cdiff Test to detect Clostridium difficile in stool specimens in markets that accept CE Mark. The test is performed on Roche…

    Published on 3/24/2014
  • Shire sales and marketing update

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic Shire recalled three lots of Vpriv velaglucerase alfa in the U.S. due to the presence of visible particulate matter in vials. The company …

    Published on 3/24/2014
  • Trovagene sales and marketing update

    Trovagene Inc. (NASDAQ:TROV), San Diego, Calif. Business: Diagnostic Trovagene launched its Urine-Based K-Ras Oncogene Mutation Assay. The laboratory-developed test (LDT) detects and monitors the seven most prevalent …

    Published on 3/24/2014
  • Access Pharmaceuticals, Hanmi Pharmaceutical sales and marketing update

    Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Business: Other Access granted Hanmi exclusive rights to commercialize MuGard in South Korea. …

    Published on 3/17/2014
  • Alexza, Ferrer sales and marketing update

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Neurology Ferrer launched Adasuve loxapine in Romania to treat mild to moderate agitation in …

    Published on 3/17/2014
  • Bacterin sales and marketing update

    Bacterin International Holdings Inc. (NYSE-M:BONE), Belgrade, Mont. Business: Musculoskeletal Bacterin launched OsteoSTX for use in orthopedic procedures, including multi-level spine procedures and deformity cases. The …

    Published on 3/17/2014
  • GenoSpace, PathGroup, Thomson Reuters Corp. sales and marketing update

    GenoSpace LLC, Cambridge, Mass. PathGroup, Brentwood, Tenn. Thomson Reuters Corp. (NYSE:TRI; TSX:TRI), New York, N.Y. Business: Supply/Service, Genomics, Cancer PathGroup, a private provider of pathology services, …

    Published on 3/17/2014
  • Gilead, Mylan sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Business: Infectious Mylan's Mylan Pharmaceuticals Pvt. Ltd. subsidiary launched a critical care segment in India focusing…

    Published on 3/17/2014
  • Gilead sales and marketing update

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Infectious Gilead recalled two lots of HIV drug Atripla emtricitabine/tenofovir/ efavirenz due to the presence of red silicone rubber particulates. …

    Published on 3/17/2014
  • Hepregen sales and marketing update

    Hepregen Corp., Medford, Mass. Business: ADMET Hepregen launched its Human HepatoPac kit in North America and Europe for use in evaluating metabolic turnover of chemicals in the human liver. The assay comprises a micro-…

    Published on 3/17/2014
  • Orexo sales and marketing update

    Orexo AB (SSE:ORX; OTCQX:ORXOY), Uppsala, Sweden Business: Neurology Orexo entered into a multi-year agreement with UnitedHealth Group Inc. (NYSE:UNH, Minnetonka, Minn.) and mail order pharmacy OptumRx Inc. (Irvine, …

    Published on 3/17/2014
  • Pfizer sales and marketing update

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Neurology Pfizer is recalling three lots of Effexor XR venlafaxine after a pharmacist reported that one bottle contained one capsule of Tikosyn dofetilide. Effexor is a …

    Published on 3/17/2014
  • Ranbaxy sales and marketing update

    Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Gurgaon, India Business: Generics, Endocrine/Metabolic Ranbaxy said that in January it recalled two lots of its 10 mg generic tablet formulation of cholesterol drug …

    Published on 3/17/2014
  • Response Genetics sales and marketing update

    Response Genetics Inc. (NASDAQ:RGDX), Los Angeles, Calif. Business: Pharmacogenetics Response Genetics launched in the U.S. an expanded K-Ras (KRAS) assay which now covers mutations on exons 2, 3 and 4. The company's …

    Published on 3/17/2014
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche launched the Elecsys Syphilis immunoassay diagnostic test in countries that recognize CE Mark approval to detect syphilis and screen donor …

    Published on 3/17/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993